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Abstract
Background Little is known regarding the impact of acute kidney injury (AKI) on renal transplant outcome. Our aim was 
to define the incidence and outcome of AKI in renal transplant patients using data collected from a national AKI electronic 
alert system
Methods The study represents a prospective national cohort study collecting data on 1224 renal transplants recipients with 
a functioning renal transplant, between April 2015 and March 2019.
Results Four hundred forty patients experienced at least one episode of AKI giving an incidence rate of 35.4%. Sixty-four 
point seven% of episodes were AKI stage 1, 7.3% AKI stage 2 and 28% AKI stage 3. Only 6.2% of episodes occurred in the 
context of rejection. Forty-three point five% of AKI episodes were associated with sepsis. AKI was associated with pre-
existing renal dysfunction, and a primary renal diagnosis of diabetic nephropathy. AKI was more prevalent in recipients from 
a donor after cardiac death (26.4% vs. 21.4%, p < 0.05) compared to the non-AKI cohort. Following AKI, 30-day mortality 
was 19.8% and overall mortality was 34.8%, compared to 8.4% in the non AKI cohort (RR 4.06, 95% CI 3.1–5.3, p < 0.001). 
Graft survival (GS), and death censored graft survival (DCGS) censored at 4 years, in the AKI cohort were significantly 
lower than in the non AKI group (p < 0.0001 for GS and DCGS).
Conclusion The study provides a detailed characterisation of AKI in renal transplant recipients highlighting its significant 
negative impact on patient and graft survival.
Keywords Renal transplant · Acute kidney injury · Outcome · Graft survival
Introduction
Acute Kidney Injury (AKI), is associated with increased 
patient morbidity and mortality [1, 2]. The majority of 
publications characterizing AKI are dependent on making 
and recording the diagnosis of AKI through either hospital 
coding or a retrospective review of hospital records [3–6]. 
An automated real time electronic (e)-alert system for AKI 
based on the Kidney Disease: Improving Global Outcomes 
(KDIGO) change in creatinine diagnostic criteria has been 
implemented across all areas of the National Health Ser-
vice in England and Wales, with the aim of facilitating early 
identification and intervention, and the presumption that this 
will influence clinical outcomes. To generate the alert the all 
Wales Laboratory Information Management System (LIMS) 
(Intersystems TrakCare Lab) automatically compares meas-
ured serum creatinine (SCr) values on an individual patient 
against previous results on the system database. We devel-
oped a centralized data collection system based on these 
alerts, and previously published a comprehensive charac-
terization of the incidence of AKI identified by an electronic 
alert, and its outcome in the general population of Wales 
[7–9].
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Data related to the incidence and outcome of AKI in the 
context of renal transplantation are scarce, and in the main 
rely on making and recording an accurate diagnosis of AKI 
through hospital coding or retrospective review of hospi-
tal records [10–12], and relate to relatively short follow up 
of patients following transplantation and relatively small 
patient numbers [13–15]. The most recent data however, 
using hospital discharge coding data, suggest that the inci-
dence of hospitalisations for AKI among kidney transplant 
recipients is rising [10]. We have previously demonstrated 
that in the general population a focus on hospitalised patients 
with a diagnosis based on retrospective coding data leads to 
significant under-reporting of AKI compared to electronic 
AKI alerts [7, 8, 16].
The current study uses a national population-based data 
set to describe the incidence and outcome of AKI in renal 
transplant recipients with AKI identified by an automated 
biochemistry-based electronic AKI alert.
Methods
Data from all Health boards in the National Health Service 
in Wales, representing a population of 3.06 million people, 
was collected from the LIMS on all patients aged 18 yrs 
or over between 1st April, 2015 and 31st March, 2019 that 
generated an AKI e-alert. The NHS Number, a unique refer-
ence number allocated to patients registered with the NHS in 
England, Wales and the Isle of Man, was used as the patient 
identifier to cross reference with the Welsh National Renal 
database, to identify prevalent transplant patients with and 
without AKI over the study period. This included any patient 
with a functioning kidney graft at any time during the study 
period. Only renal transplant recipients aged 18 years or 
older with a time since transplantation greater than 90 days 
were included. The study was approved under the terms of 
Service Evaluation Project Registration.
The AKI alert is generated by comparing in real time a 
current SCr value with historic SCr measurements for the 
same patient. It defines AKI according to KDIGO increase 
in creatinine parameters [7]. Patients were only included in 
the study if the AKI alert was generated from a baseline 
creatinine related to a functioning transplant, i.e. no patients 
had baseline generated from a creatinine related to a period 
on dialysis. We have previously demonstrated that this 
approach ensures collection of all AKI episodes highlighted 
by an electronic alert across the country, regardless of the 
clinical location, and excludes patients with end stage renal 
failure (ESRF), receiving renal replacement therapy (RRT). 
The AKI Alerts are displayed alongside the biochemical 
results on the pathology reporting system and consist of one 
of the following text statements which provide context to the 
change in creatinine for the receiver:
(a) Trigger ≥ 26 μmol/l increase in creatinine within 48 h, 
Associated alert; Acute Kidney Injury alert: rising cre-
atinine within last 48 h.
(b) Trigger ≥ 50% increase in creatinine within 7 days; 
Associated alert; Acute Kidney Injury alert: rising 
creatinine within last 7 day.
(c) Trigger = 50% increase in serum creatinine against 
median result for 8–365 days, Associated alert; Acute 
Kidney Injury alert—creatinine increase over baseline 
value.
An AKI episode was defined as 30 days, with the first 
AKI alert defined as the incident alert. Any alert for the 
same patient within 30 days of the incident alert was not 
considered a new episode. For patients with multiple 
episodes, their first episode was defined as their index 
episode.
Data on patient mortality was collected from the Welsh 
Demographic Service [17]. Recovery of renal function was 
defined as a SCr value during the episode no longer in 
keeping with the definition of AKI when compared to the 
baseline SCr value associated with the same episode. Only 
surviving patients who had at least one SCr test during 
the episode were included in the recovery analysis. Pre-
study baseline renal function for those transplant recipi-
ents with a transplant date of more than 90 days before 
the study start date of 1st April, 2015 was defined using 
the last SCr value recorded before the study start date. For 
all other transplant recipients, the last SCr value recorded 
before date of transplant + 90 days was used. Post-study 
renal function was defined as the latest SCr value recorded 
after the end of the study period. Estimated glomerular 
filtration rate (eGFR) was calculated using the CKDEpi 
eGFR formula. A greater than 15% deterioration in the 
eGFR or a deterioration in eGFR greater than 5 ml/min 
from the baseline renal function of the patient at the date 
of entry into the study was used to indicate a significant 
deterioration in renal function over the course of the study. 
Only those patients still living with a functioning graft at 
the end of the study period were included in the analysis 
of this variable.
Statistical analysis was carried out using SPSS soft-
ware, version 25 (IBM SPSS, Chicago, IL). Student’s t test 
was used for analysis of normally distributed data. Cat-
egorical data were compared using a Pearson Chi-squared 
test. Kaplan Meier analysis was used to estimate and 
compare survival of patient groups. Multivariate Binary 
Logistic Regression was used to assess the association of 
baseline SCr, AKI stage, Age at AKI, Age at transplant, 
Recurrent AKI, and Donor type with overall patient sur-
vival, overall patient and graft survival, and overall renal 
recovery from AKI.
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Results
In a total of 1224 renal transplants, 440 patients experienced 
at least one episode of AKI giving an incidence of AKI of 
35.4% over the study period (Table 1). In total there were 
937 episodes of AKI with roughly half (224) of the patients 
who experienced an AKI episode experiencing more than 
one AKI episode. For patients with multiple episodes, mean 
number of episodes was 3.2 ± 2.1. The majority (64.7%) of 
episodes were classified as AKI stage 1 at presentation, with 
7.3% AKI stage 2 and 28% AKI stage 3.
The mean age of the AKI cohort of transplant recipi-
ents was no different to those with no AKI (47.2 ± 15.4 vs. 
46.2 ± 14.7 yrs). There was no difference in gender distribu-
tion between the AKI and non-AKI patients (38.2% were 
female in the AKI vs. 35.3% in the non-AKI group, p = 0.3). 
Similarly, the average time since transplant to inclusion in 
the study was also no different between the AKI and non-
AKI cohort (1942 ± 2350 vs. 1998 ± 2380 days). In con-
trast, the mean baseline serum creatinine was significantly 
higher in the AKI cohort compared to the non-AKI cohort 
(173.0 ± 127.2 vs. 128.1 ± 51.2 μmol/l). The aetiologies of 
underlying end-stage renal disease of transplant patients 
are shown in Table 1. Diabetic nephropathy as a primary 
renal diagnosis was more common in the AKI cohort. There 
were no differences in the distribution of all other primary 
diagnoses.
Within the AKI cohort there were significantly more 
patients receiving a transplant from a donor after cardiac 
death (26.4% vs. 21.4%, p < 0.05) and less from live related 
donation (23.6% vs. 33.7%, p < 0.001) compared to the non-
AKI cohort.
The clinical locations of the blood test resulting in the 
incident AKI alert are shown in Fig. 1. Roughly half of 
the AKI episodes were associated with an alert related to a 
Table 1  Characteristics of 
transplant patients who had AKI 
vs. patients who had no AKI
AKI No AKI p value
Number of patients, n (number of transplants) 440 (440) 771 (784)
Number of AKI episodes 937 –
Mean age at time of transplant ± SD (years) 47.2 ± 15.5 46.2 ± 14.7 p = NS
% Female 38.2 35.3 p = NS
Primary renal diagnosis % (n)
 Polycystic kidney disease 12.5 (55) 14.5 (112) p = NS
 IgA nephropathy 11.8 (52) 13.5 (104) p = NS
 Diabetic nephropathy 14.1 (62) 9.6 (76) p = 0.026
 Reflux nephropathy 6.1 (27) 7.1 (55) p = NS
 Glomerulonephritis 10.2 (45) 11.4 (88) p = NS
 Primary FSGS 3.2 (14) 3.4 (26) p = NS
 Hypertensive nephrosclerosis 2.5 (11) 2.7 (21) p = NS
 Idiopathic membranous glomerulonephritis 1.6 (7) 1.4 (11) p = NS
 Other 11.8 (52) 14.1 (109)
 Unknown 9.6 (42) 7.4 (57)
 Diagnosis not recorded 16.6 (73) 14.5 (112)
Time from transplant to start of study ± SD (days) 1942 ± 2350 1998 ± 2380 p = NS
Mean baseline Creatinine ± SD (mmol/l) 173.0 ± 127.2 128.1 ± 51.2 p < 0.001
Donor type % (n =)
 Donor after brain death 49.5 (218) 44.9 (352) p = NS
 Donor after cardiac death 26.4 (116) 21.4 (168) p < 0.05
 Live related donor 23.6 (104) 33.7 (264) p < 0.001
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Fig. 1  Clinical locations at which the blood test resulting in the AKI 
alert was generated
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nephrology request, the majority of which were a result of a 
blood test requested in a transplant out-patient setting. Of the 
remaining AKI episodes, the majority of alerts were reported 
following requests from general medical in-patients (7.9%), 
Accident and Emergency (7.9%), primary care (6.3%) and 
general medical out patients (6.1%).
Natural history of AKI in renal transplant recipients 
(Table 2)
Following an AKI episode, 30-day mortality was 19.8% and 
overall mortality over the study period was 34.8%. Baseline 
serum creatinine was significantly higher in the cohort of 
AKI patients who died compared to the surviving patients 
(210.29 ± 173.1 vs. 153.5 ± 89.2 μmol/l, p = 0.0002). More 
than one episode of AKI was associated with higher overall 
patient mortality compared with patients with only one epi-
sode (41.1% vs. 28.2%, RR 1.5, 95% CI 1.1–1.9, p = 0.005). 
In those patients who survived an episode of AKI and had 
follow-up biochemistry data available, recovery of renal 
function occurred in 75% of episodes. In the surviving 
group severity of AKI was a determinant of recovery of renal 
function, which was lower in patients with incident stage 2 
or 3 AKI alerts compared with stage 1 (56.8% vs. 70.5%, 
P < 0.001). There was no association between non-recovery 
of renal function and overall patient mortality, with a 29% 
mortality rate for those that recovered compared to 31.6% 
for those that did not. There was also no association between 
non-recovery and repeated AKI episodes, with 52.3% of 
patients that recovered their index episode experiencing at 
least one further episode, compared to 60.7% of those that 
did not recover their renal function in their index episode.
Multivariate Binary Logistic Regression showed that a 
lower baseline SCr (B = − 0.01, p < 0.001) and age at AKI 
(B = − 0.07, p < 0.001) were associated with an increased 
likelihood of overall patient survival, and patients with 
multiple AKI episodes were less likely to survive com-
pared to those who had a single episode (OR = 0.47, 95% 
CI 0.30–0.75, p < 0.001). Similarly, a lower baseline 
SCr (B = − 0.01, p < 0.001) and age at AKI (B = − 0.07, 
p < 0.015) were also associated with an increased likeli-
hood of overall patient and graft survival. Patients with AKI 
stage 3 were less likely to survive with a functioning graft 
compared to those with AKI stage 1 (OR = 0.46, 95% CI 
0.25–0.86, p = 0.014), as was the case with patients with 
multiple AKI episodes compared to patients with a single 
episode (OR = 0.39, 95% CI 0.25–0.61, p < 0.001). Further-
more, a lower baseline SCr (B = − 0.01, p = 0.048) lower 
age at AKI (B = − 0.05, p = 0.011), and higher age at trans-
plant (B = 0.05, p = 0.011) were associated with an increased 
likelihood of overall renal recovery from AKI, and patients 
with multiple AKI episodes were far less likely to recover 
compared to those who had a single episode (OR = 0.28, 
95% CI 0.17–0.47, p < 0.001).
Our previous work in non-transplant associated AKI has 
demonstrated that a significant proportion of patients high-
lighted with an AKI alert do not have further monitoring 
of renal function. In this transplant recipient cohort 96.1% 
of the AKI episodes were associated with a repeat measure 
of renal function within 7 days of the alert, with a mean 
time to repeat of 3.8 ± 5.9 days. It should be noted however 
that in 37 episodes no repeat measure of renal function was 
requested within 7 days of the incident alert.
The clinical diagnosis associated with each AKI episode 
is shown in Table 3. Rejection was associated with only 
Table 2  Natural history of AKI in Renal Transplantation
Recovery of renal function included only surviving patients with available tests of follow-up renal function: 710 episodes were included in the 
30-day recovery of renal function analysis (484 episodes, CA; 226 episodes, HA-AKI)
Whole AKI cohort CA-AKI HA-AKI p value CA 
vs. HA-AKI
Number of AKI episodes, n (% of whole cohort) 937 538 (57.4) 273 (29.1)
Mean age at time of AKI ± SD (years) 55.2 ± 14.7 53.2 ± 14.6 59.6 ± 13.2 p < 0.001
AKI stage 1, % (n) 64.7 (606) 64.5 (312) 78.4 (214) p < 0.001
AKI stage 2, % (n) 7.3 (68) 7.8 (42) 6.6 (18) p = n/s
AKI stage 3, % (n) 28.0 (263) 34.2 (184) 18.4 (41) p < 0.001
Outcome measures
 30-day mortality, % (n) 19.8 (87) 4.8 (26) 16.8 (46) p < 0.001
 Overall mortality, % (n) 34.8 (153)
 30-day recovery of renal function, % (n) 75 (615) 70.2 (340)̂ 81.8 (185) p < 0.001
Process measures
 Repeat test within 30 days, % (n) 96.1 (900) 93.9 (505) 98.8 (270) p = 0.001
 Mean time to repeat ± SD (days) 3.8 ± 5.9 5.5 ± 7.13 1.43 ± 1.87 p < 0.001
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6.2% of all episodes. This cohort was significantly younger 
than the non-rejection group, and had a higher proportion 
of AKI stage 3 at presentation. In the non-rejection cohort, 
the predominantly associated clinical diagnosis was sepsis, 
with urinary tract and respiratory infection accounting for 
the majority of cases. There were no differences in mortal-
ity between the rejection- and non-rejection-associated AKI 
episodes. Recovery of renal function was however signifi-
cantly worse following rejection-associated AKI, reflecting 
the higher proportion of stage 3 AKI at presentation.
Comparison of hospital‑ and community‑acquired 
(HA)/(CA) transplant‑associated AKI
CA-AKI accounted for 57.4% of all episodes (n = 538), of 
which hospitalisation following the alert occurred in only 
37 episodes. Transplant out-patients’ requests accounted 
for 61.3% of CA-AKI. The other major sources of CA-AKI 
alerts were Accident and Emergency (13.9%), Primary care 
(11.0%) and medical out-patients (10.6%).
HA-AKI accounted for 29.1% (273) of all transplant-asso-
ciated AKI. For hospital-acquired AKI, the largest single 
cohort was reported following a blood test requested from 
the renal transplant in-patient ward (49.8%), followed by 
general medical in-patients (27.1%), cardiology in-patients 
(13.9%), general surgery in-patients (13.5%), and intensive 
treatment unit (ITU) (11.7%). The remaining 13.4% (126) 
of alerts were generated in an in-patient setting, but as no 
results were available for the previous 7 days it was not pos-
sible to confidently classify these as either CA- or HA-AKI.
The proportion of incident AKI alerts reported as AKI 
stage 3 was significantly higher in CA-AKI compared to 
HA-AKI (Table 2). Conversely the proportion of AKI stage 
1 was lower in the CA-AKI group compared to HA-AKI. 
Compared to CA-AKI, 30-day mortality was significantly 
higher for patients following HA-AKI (HA-AKI: 16.8% 
vs. CA-AKI: 4.8%, p = 0.001). In contrast to mortality out-
comes, for the surviving patients recovery of renal func-
tion at 30-days was significantly better following HA-AKI 
(HA-AKI; 81.8% vs. CA-AKI: 70.2%, p < 0.001). Within 
the CA-AKI cohort the mean time to repeat measurement 
was 5.5 ± 7.1 days; following 33 AKI episodes there were 
no repeat measures of renal function within 7 days of the 
alert. In contrast, in the HA AKI cohort, there were no repeat 
measures of renal function within 7 days following only 3 
AKI episodes, and the average time to repeat was signifi-
cantly shorter than in CA-AKI (1.4 ± 1.9 days, p < 0.001).
Influence of AKI on transplant patient outcomes 
(Table 4)
Mortality censored at 4 years was significantly higher in the 
AKI cohort compared to those who did not have an AKI 
episode during the study period (p < 0.0001, Fig. 2a). Over-
all mortality for the non AKI cohort was 8.4% compared to 
Table 3  Clinical course by clinical diagnosis associated with AKI episode
Details of clinical diagnosis associated with AKI were not available for 187 episodes. Mortality data were available for 692 non-rejection epi-
sodes and 58 rejection episodes. Recovery of renal function included only surviving patients with available tests of follow-up renal function: for 
non-rejection AKI recovery included 608 episodes and for rejection 53 episodes. For the sepsis-associated AKI group mortality data were avail-
able for all 408 episodes, recovery of renal function included 364 episodes
*p < 0.001 compared to Non rejection AKI
Number of epi-
sodes (%)
Mean age ± SD (years) AKI stage (% of 
episodes)
30-day mortality, 
% (n)
30-day recovery 
of renal function, 
% (n)
Non-rejection, n (%) 692 (73.9) 56.11 ± 14.5 1: 67.5
2: 9.1
3: 23.4
9.39 (65) 79.7 (486)
Sepsis, n (%)
(Urinary)
(Respiratory)
408 (43.5)
(171)
(11)
56.38 ± 14.63 1: 67.9
2: 10.3
3: 21.8
8.3 (34) 89.2 (364)
Dehydration 142
Cardiac 27
Obstruction 16
Recurrent disease 14
Contrast 7
Other 65
Rejection, n (%) 58 (6.2) 44.91 ± 16.3* 1: 53.4*
2: 3.4
3: 43.1*
5.17 (3) 49.06 (26)
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34.8% in the AKI group (RR 4.1, 95% CI 3.1–5.3, p < 0.001 
compared to AKI cohort).
A comparison of the status of the patients at the end of the 
study period demonstrated significantly fewer patients alive 
with a functioning graft in the AKI group. More patients 
were alive with a non-functioning graft, and a higher pro-
portion of patients had died, either with a functioning graft 
or with a non-functioning graft, in the AKI group. The 
association between AKI and graft failure was analysed by 
Kaplan–Meier estimation. Graft survival (GS), and death 
censored graft survival (DCGS) censored at 4 years, in the 
AKI cohort were significantly lower than in the non AKI 
group (p < 0.0001 for both GS and DCGS, Fig. 2b and c).
For patients who had poststudy renal function data 
available (i.e. alive with a functioning graft) the pre-study 
baseline renal function was no different in the AKI group 
compared to the non-AKI group (133.4 ± 52.0 μmol/l vs. 
123.9 ± 17.3 μmol/l). In contrast, post-study serum cre-
atinine was significantly higher in the AKI cohort com-
pared to the non-AKI cohort (167.6 ± 82.4  μmol/l vs. 
123.8 ± 50.7 μmol/l, p < 0.001). Similarly, whilst the eGFR 
was not significantly different at the beginning of the study 
(50.5 ± 18.1 ml/min for the AKI cohort vs. 53.9 ± 17.3 ml/
min for the non-AKI cohort), at the end of the study 
period those from the AKI cohort had a significantly lower 
eGFR compared to the non-AKI group (42.3 ± 20.7 ml/
min vs. 55.4 ± 20.1 ml/ml, p < 0.001). The percentage of 
patients with an end of study period renal function which 
was worse than the starting renal function as defined by 
a greater than 15% or 5 ml/min deterioration in eGFR, 
Table 4  Comparison of 
outcomes AKI vs No AKI in 
renal transplantation
927 patients were included in analysis of the renal function at the end of the study variable (AKI, 221; No 
AKI, 706)
AKI No AKI p value
Number of patients 440 771
Mean duration of follow up since Trans-
plant ± SD (days)
3669.6 ± 2701.7 3515.7 ± 2780.3 p = 0.34
Overall mortality, % (n) 34.8 (153) 8.6 (66) p < 0.001
Patient status at end of study
 Living with functioning graft 50.2 (221) 91.6 (706) p < 0.001
 Living with non-functioning graft 15.0 (66) 1.6 (12) p < 0.001
 Died with functioning graft 30.0 (132) 8.3 (64) p < 0.001
 Died with non-functioning graft 4.8 (21) 0.3 (2) p < 0.001
Renal function at end of study
 Creatinine mmol/l (mean ± SD) 167.6 ± 82.4 123.8 ± 50.7 p < 0.001
 eGFR (ml/min) (mean ± SD) 42.3 ± 20.7 53.9 ± 17.3 p < 0.001
 % with significantly worse renal function 57 24.5 p < 0.001
Fig. 2  Impact of AKI on patient and graft survival. a 4 year censored 
survival of renal transplant patients experiencing at least one AKI 
episode compared to renal transplant recipients with no episodes of 
AKI during the study period. Renal graft survival (b) and death cen-
sored renal graft survival, both censored at 4 years, in patients expe-
riencing at least one AKI episode compared to renal transplant recipi-
ents with no episodes of AKI during the study period
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was also higher in the AKI group (57.0% vs. 24.5%, RR 
2.3 95% CI 1.9–2.7, p < 0.001). The duration of follow up 
from the time of transplant was no different between these 
two groups (3669.6 ± 2701.7 days for the AKI group vs. 
3515.7 ± 2780 days for the non-AKI group, p = 0.34).
Discussion
Studies on AKI in renal transplant recipients are scarce but 
report a 40–50 fold higher incidence than the general popu-
lation [11, 13], and occurring in up to 85% of hospitalised 
renal transplant patients [14]. It is postulated that the nature 
of AKI in renal transplants may be different to that seen in 
the general population with different susceptibilities related 
to denervated kidneys, susceptibility to haemodynamic 
instability, use of nephrotoxic drugs, especially calcineu-
rin inhibitors, immune-related injury and predisposition to 
opportunistic infections. Whilst numerous published stud-
ies have described acute renal dysfunction in the immediate 
post-transplant phase [15, 18–22], very little is known of 
the nature and impact of AKI in the “maintenance” phase 
of renal transplantation. To address this, our focus was on 
AKI beyond the first 90 days of transplantation and well into 
the maintenance phase of prevalent renal transplant patients.
Our data report an incidence of AKI of 35%. In contrast, 
Mehrota et al. reported an AKI incidence of 11.3% in trans-
plant patients in a study confined to hospitalised patients 
only, and identified AKI using coding data [11]. Our higher 
incidence may in part be explained by the high incidence 
of non-hospitalised AKI in renal transplant patients that 
we have identified but not previously reported. In contrast, 
a 51% incidence rate of transplant-associated AKI was 
reported by Nagarajan et al. [12]. That study focused on a 
relatively short term period of follow up, with AKI occur-
ring predominantly in the first year of the follow up period. 
This higher reported incidence may therefore reflect the 
greater burden of AKI in the early phase following trans-
plantation compared to our data which are of AKI occur-
ring later in the phase of the prevalent transplant population. 
Nakamura et al., in contrast, reported an AKI incidence of 
20.4% in transplant recipients, which is significantly less 
than our reported incidence. In this study, with a mean fol-
low up period of four years post-transplantation, the majority 
of the AKI occurred within two years of the transplant [13], 
and AKI was only identified through nephrology/transplant 
clinics. Our non-selective approach, which identified all 
AKI based on every blood test that a prevalent renal patient 
had at any location, highlights that such an approach will 
significantly underestimate the true incidence of transplant-
associated AKI.
In terms of clinical outcome, whilst AKI in the context 
of renal transplant carries a significant short term (30-day) 
and longer term mortality, this is similar to our previously 
reported data in the adult population [7, 23, 24], suggest-
ing there is no excess in mortality when AKI occurs in 
renal transplant recipients compared to the general popu-
lation. Our data also demonstrate that poor renal function 
prior to an AKI episode is associated with higher mortality. 
Although renal function in the immediate period following 
the AKI episode recovered in three-quarters of cases, AKI 
impacted negatively on graft survival and function, with a 
higher rate of graft loss, and significantly worse renal func-
tion in surviving patients in the AKI cohort. This is con-
sistent with the previously published hospital-based, single 
centre and relatively small studies suggesting an association 
between AKI and risk of transplant loss [11–14]. Although 
the mechanistic link between AKI and graft loss remains 
speculative, it has been proposed that an episode of AKI may 
up-regulate inflammatory and fibrotic signalling pathways, 
leading to progressive structural kidney damage [25–28].
The only demographic differences between our AKI 
and non-AKI cohort was a higher prevalence of diabetic 
nephropathy as the cause of ESRF, and a higher serum 
creatinine at baseline. This is similar to the findings of the 
studies by Nakamura et al. [13] and Mehrotra et al. [11] 
demonstrating an association between post-transplant AKI, 
renal function and diabetes. For the general population, both 
diabetes [29–32] and CKD [33, 34] have previously been 
described in the literature as risk factors for AKI. In this con-
text at least, our data would suggest the transplant population 
is therefore similar to the general adult population in terms 
of AKI risk. The higher baseline SCr in the AKI cohort 
along with the fact that patients with AKI had a conceivably 
higher prevalence of chronic graft dysfunction and a higher 
prevalence of the related alloimmune and non-alloimmune 
causes of chronic graft dysfunction suggest AKI may repre-
sent more a marker of clinical frailty rather than playing a 
direct pathogenetic role towards the risk of death and graft 
failure. It is of note that the prevalence of a kidney from a 
deceased donor was higher in our AKI cohort. This is con-
sistent with previous published data highlighting deceased 
donor transplant to be a significant risk factor for the devel-
opment of AKI [12]. This may be related to the incidence of 
delayed graft function and resultant renal impairment in this 
cohort, although this remains speculative as we were unable 
to report on delayed graft function in our study.
In the non-transplant population, in the majority of cases, 
AKI does not reflect intrinsic kidney disease but is rather a 
complication of other primary illnesses. Our data suggest 
that this is also reflected in transplant patients. In this study 
AKI in the context of the maintenance phase of renal trans-
plant does not represent either rejection or recurrence of 
the primary renal disease. The majority of cases are associ-
ated with a clinical diagnosis of sepsis, with roughly a half 
identified via a non-nephrology/transplant request. This is 
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consistent with the work of Nakamura et al. demonstrat-
ing that bacterial infections and predominantly urinary 
tract infections were the most common aetiological factors 
contributing to renal-transplant-associated AKI, although 
this study was confined to a small number of living donor 
recipients alone and in the setting of the outpatient nephrol-
ogy/transplant clinic [13]. This pattern of AKI is however 
different to that reported in the early post operative period 
when the nephrotoxic effect of immunosuppressive agents, 
in particular calcineurin inhibitors and rejection, are more 
common [15].
Our data demonstrate that over half of transplant-asso-
ciated AKI is detected in the community, with only a small 
minority of cases being admitted to hospital. These cases 
therefore would not be reported in studies based on hospi-
talisation, nor would AKI identified through hospital coding. 
Although HA-AKI in this study represents roughly a third 
of the AKI cases, it should be noted that there were also a 
significant number of episodes classified as ‘undetermined 
in hospital alerts’, as these patients, whilst alerting in an in-
patient setting, had no results for the previous 7 days. Our 
data therefore likely reflect a significant underestimation of 
the true incidence of HA-AKI in renal transplant recipients. 
Mortality following HA-AKI in this transplant cohort was 
significantly higher than following CA-AKI. This higher 
mortality is not a reflection of AKI severity per se, as there 
was a higher proportion of incident AKI stage 3 alerts in 
the CA-AKI group. The higher mortality in the HA-AKI 
cohort again mirrors our previous data in the general adult 
and paediatric populations [9, 35]. As the majority of AKI 
cases do not represent intrinsic kidney disease it is likely 
that the excess mortality in HA-AKI reflects the severity of 
the primary illness precipitating AKI. Previously we have 
demonstrated that in the general adult and paediatric popu-
lations, in those surviving an AKI episode, renal function 
is better following HA- compared to CA-AKI [7–9, 16]. In 
part at least this reflects clinical inactivity and a failure to 
recognise the importance of the alert. This was supported 
by the lower number of patients with CA-AKI compared 
to HA-AKI who have a repeat measure of creatinine even 
following severe AKI, and a longer time to repeat for those 
who do have a repeat measure. It is of note that few patients 
in the transplant cohort did not have any follow-up bloods, 
however, as in the general non-transplant adult population, in 
this study of transplant patients the time to repeat a measure 
of renal function was significantly longer in the CA-AKI 
group which may reflect a slower response time that may 
then in turn result in later initiation of interventions which 
may facilitate recovery of renal function.
Although this study is to our knowledge the first national 
study using an e-alert-based system to characterise the mag-
nitude and impact of AKI in renal transplant recipients, its 
findings need to be qualified by its limitations. As the e-alert 
system is IT driven it lacks “intelligence” and therefore there 
is no clinical context applied. Using an IT-based approach 
also excludes patient clinical information, such as patient 
co-morbidities, medication. Linkage to comorbidity data 
in particular would have helped strengthen the suggestion 
made by this study that AKI may represent more a marker of 
clinical frailty rather than playing a direct pathogenetic role 
towards the risk of death and graft failure. We are also una-
ble to generate linkage to primary care data sets. As a con-
sequence, a detailed analysis of the clinical response to the 
AKI episode cannot be captured. Our data also lack details 
on the need for RRT, and do not shed light on the cause 
of death. Our data report the incidence of AKI in which 
the diagnosis is a creatinine-based definition in which the 
baseline creatinine is generated by the patients’ historical 
results. As such, this may not meet the strict agreed AKI 
definition of “abrupt deterioration”, and does not take into 
account a “urine output”-based AKI diagnosis. Despite these 
limitations our study provides a detailed characterisation of 
AKI in renal transplant recipients and highlights its impact 
on patient and graft survival.
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